Evidence map›Paper›PMID 41565684›Full record

ArticleNature communications2026

PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

Sixuan Pan, Inés Fernández-Maestre, Kai-Chun Chang, Stéphane Van Haver, Matthew G Wereski, Alexandra M Haugh, Katy K Tsai, Adil I Daud, Robert L Bowman, Harish N Vasudevan and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sixuan Pan *Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0001-3795-4903
Inés Fernández-Maestre *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kai-Chun ChangDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7200-3532
Stéphane Van HaverMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew G WereskiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexandra M HaughDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Katy K TsaiDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Adil I DaudDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6617-8421
Robert L BowmanDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8294-8748
Harish N VasudevanDepartments of Radiation Oncology and Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9633-1100
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leviner@mskcc.org.ORCID http://orcid.org/0000-0002-7884-1905
Adam R AbateDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. arabate@gmail.com.ORCID http://orcid.org/0000-0001-9614-4831

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Synergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4M
Multi-omic dissection of the transcriptional, epigenetic, and proteomic signatures of cells infected with latent HIVR01AI149699 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABATE, ADAM R., QUINTANA, FRANCISCO J. · 2020 to 2024
$3.8M
Inflammatory Signaling in DNMT3A-Mutated Human Hematopoietic Stem CellsU01AG077925 · NIA · JACKSON LABORATORY · PI LEVINE, ROSS L, TROWBRIDGE, JENNIFER JEAN · 2021 to 2025
$2.9M
Identification of Regulatory Mechanisms Operating in Rare Pathogenic Astrocyte Subsets in Multiple Sclerosis with a Novel Genomic TechnologyR01NS130876 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adam R. Abate, CARLO L CONDELLO · 2023 to 2026
$2.3M
Interrogating oncogene-dependency and mutation order in FLT3 mutant AMLK99CA248460 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOWMAN, ROBERT LYLE · 2020 to 2021
$297k
uNDERSTANDING AND TARGETING SENESCENCE IN CLONAL HEMATOPOIESISK00CA284253 · NCI · COLD SPRING HARBOR LABORATORY · PI FERNANDEZ MAESTRE, INES · 2025 to 2025
$101k
Identifying Inflammatory Mediators of Clonal HematopoiesisF99CA284253 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FERNANDEZ MAESTRE, INES · 2023 to 2024
$75k
NCI NIH HHS F99 CA284253NCI NIH HHS K00 CA284253NCI NIH HHS K99 CA248460NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA197594NIAID NIH HHS R01 AI149699NIA NIH HHS U01 AG077925NINDS NIH HHS R01 NS130876U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01NS130876
6 · The paper itself

Abstract

Single-cell transcriptomics is valuable for uncovering individual cell properties, particularly in heterogeneous systems. However, this technique often results in the reanalysis of many well-characterized cells, increasing costs and diluting rare cell populations. To address this, we develop PIP-seq for Rare-cell Enrichment and Sequencing (PURE-seq). PURE-seq allows direct FACS sorting of cells into PIP-seq reactions, minimizing handling and reducing cell loss. PURE-seq reliably sequences ultrarare cells, with 1 hour of sorting capturing tens of target cells at a rarity of 1 in 1,000,000. Leveraging this extreme sensitivity, we use PURE-seq to isolate and single-cell sequence circulating tumor cells from metastatic melanoma patient blood, obtaining detailed single cancer cell gene expression profiles. Additionally, we use PURE-seq to examine hematopoietic stem and progenitor cells from young, old and middle-aged mice. Transcriptomic analysis identifies Egr1 as a putative master regulator of murine hematopoietic stem and progenitor cell aging, demonstrating PURE-seq's utility as a discovery platform for basic science applications. PURE-seq offers a simple and highly sensitive method for single-cell sequencing ultra-rare cells.

Indexed as

Flow CytometryGenomicsSingle-Cell AnalysisAnimalsEarly Growth Response Protein 1Gene Expression ProfilingHematopoietic Stem CellsHigh-Throughput Nucleotide SequencingHumansMelanomaMiceNeoplastic Cells, CirculatingSingle-Cell Gene Expression AnalysisEarly Growth Response Protein 1EGR1 protein, human

Identifiers

PMID41565684
PMCPMC12881479

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.